ID

21950

Descripción

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00415064

Link

https://clinicaltrials.gov/show/NCT00415064

Palabras clave

Versiones (1)
  1. 9/5/17 9/5/17 -
Subido en

9 de mayo de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Multiple Myeloma NCT00415064

Inglés

Eligibility Multiple Myeloma NCT00415064

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
subject was previously diagnosed with multiple myeloma based on standard diagnostic criteria, as follows.
Descripción

Multiple Myeloma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0026764
major criteria:
Descripción

Criteria Main

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1542147
1. plasmacytomas on tissue biopsy.
Descripción

Plasmacytoma Biopsy tissue

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0032131
UMLS CUI [1,2]
C3864006
2. bone marrow plasmacytosis (> 30% plasma cells).
Descripción

BONE MARROW PLASMACYTOSIS Plasma Cells Percentage

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0238803
UMLS CUI [1,2]
C0032112
UMLS CUI [1,3]
C0439165
3. monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin g (igg) >3.5 g/dl or immunoglobulin a (iga) > 2.0 g/dl; kappa or lambda light chain excretion > 1 g/day on 24 hour urine protein electrophoresis.
Descripción

Monoclonal immunoglobulin present | Serum electrophoresis Immunoglobulin G | Serum electrophoresis Immunoglobulin A | Free kappa light chain Excretion | Free lambda light chain Excretion | 24-hour urine protein electrophoresis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0860896
UMLS CUI [2,1]
C0851095
UMLS CUI [2,2]
C0020852
UMLS CUI [3,1]
C0851095
UMLS CUI [3,2]
C0020835
UMLS CUI [4,1]
C0443743
UMLS CUI [4,2]
C0221102
UMLS CUI [5,1]
C0443744
UMLS CUI [5,2]
C0221102
UMLS CUI [6]
C2321676
patients must have relapsed or refractory disease (refractory is defined as progression during treatment or within 60 days after the completion of treatment) requiring 2nd or 3rd line therapy
Descripción

Recurrent disease | Refractory Disease | Disease Progression | Second line treatment Patient need for | Third line treatment Patient need for

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0277556
UMLS CUI [2]
C1514815
UMLS CUI [3]
C0242656
UMLS CUI [4,1]
C1710038
UMLS CUI [4,2]
C0686904
UMLS CUI [5,1]
C2986605
UMLS CUI [5,2]
C0686904
patients refractory to a combination of lenalidomide and dexamethasone will not be eligible. patients may have received lenalidomide and/or dexamethasone
Descripción

lenalidomide | Dexamethasone | Combined Modality Therapy Patients refractory

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1144149
UMLS CUI [2]
C0011777
UMLS CUI [3,1]
C0009429
UMLS CUI [3,2]
C0030705
UMLS CUI [3,3]
C0205269
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
renal insufficiency (serum creatinine levels > 3 mg/dl)..
Descripción

Renal Insufficiency | Creatinine measurement, serum

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C0201976
history of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
Descripción

Allergic Reaction Perifosine Compound Similar | Allergic Reaction Miltefosine Compound Similar | Allergic Reaction Edelfosine Compound Similar

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1527304
UMLS CUI [1,2]
C0754570
UMLS CUI [1,3]
C1706082
UMLS CUI [1,4]
C2348205
UMLS CUI [2,1]
C1527304
UMLS CUI [2,2]
C0068006
UMLS CUI [2,3]
C1706082
UMLS CUI [2,4]
C2348205
UMLS CUI [3,1]
C1527304
UMLS CUI [3,2]
C0044549
UMLS CUI [3,3]
C1706082
UMLS CUI [3,4]
C2348205
known hypersensitivity to thalidomide
Descripción

Hypersensitivity Thalidomide

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0039736
Volver a la parte superior de la página

Similar models

Eligibility Multiple Myeloma NCT00415064

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Myeloma
Item
subject was previously diagnosed with multiple myeloma based on standard diagnostic criteria, as follows.
boolean
C0026764 (UMLS CUI [1])
Criteria Main
Item
major criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Plasmacytoma Biopsy tissue
Item
1. plasmacytomas on tissue biopsy.
boolean
C0032131 (UMLS CUI [1,1])
C3864006 (UMLS CUI [1,2])
BONE MARROW PLASMACYTOSIS Plasma Cells Percentage
Item
2. bone marrow plasmacytosis (> 30% plasma cells).
boolean
C0238803 (UMLS CUI [1,1])
C0032112 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
Monoclonal immunoglobulin present | Serum electrophoresis Immunoglobulin G | Serum electrophoresis Immunoglobulin A | Free kappa light chain Excretion | Free lambda light chain Excretion | 24-hour urine protein electrophoresis
Item
3. monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin g (igg) >3.5 g/dl or immunoglobulin a (iga) > 2.0 g/dl; kappa or lambda light chain excretion > 1 g/day on 24 hour urine protein electrophoresis.
boolean
C0860896 (UMLS CUI [1])
C0851095 (UMLS CUI [2,1])
C0020852 (UMLS CUI [2,2])
C0851095 (UMLS CUI [3,1])
C0020835 (UMLS CUI [3,2])
C0443743 (UMLS CUI [4,1])
C0221102 (UMLS CUI [4,2])
C0443744 (UMLS CUI [5,1])
C0221102 (UMLS CUI [5,2])
C2321676 (UMLS CUI [6])
Recurrent disease | Refractory Disease | Disease Progression | Second line treatment Patient need for | Third line treatment Patient need for
Item
patients must have relapsed or refractory disease (refractory is defined as progression during treatment or within 60 days after the completion of treatment) requiring 2nd or 3rd line therapy
boolean
C0277556 (UMLS CUI [1])
C1514815 (UMLS CUI [2])
C0242656 (UMLS CUI [3])
C1710038 (UMLS CUI [4,1])
C0686904 (UMLS CUI [4,2])
C2986605 (UMLS CUI [5,1])
C0686904 (UMLS CUI [5,2])
lenalidomide | Dexamethasone | Combined Modality Therapy Patients refractory
Item
patients refractory to a combination of lenalidomide and dexamethasone will not be eligible. patients may have received lenalidomide and/or dexamethasone
boolean
C1144149 (UMLS CUI [1])
C0011777 (UMLS CUI [2])
C0009429 (UMLS CUI [3,1])
C0030705 (UMLS CUI [3,2])
C0205269 (UMLS CUI [3,3])
Item Group
C0680251 (UMLS CUI)
Renal Insufficiency | Creatinine measurement, serum
Item
renal insufficiency (serum creatinine levels > 3 mg/dl)..
boolean
C1565489 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Allergic Reaction Perifosine Compound Similar | Allergic Reaction Miltefosine Compound Similar | Allergic Reaction Edelfosine Compound Similar
Item
history of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
boolean
C1527304 (UMLS CUI [1,1])
C0754570 (UMLS CUI [1,2])
C1706082 (UMLS CUI [1,3])
C2348205 (UMLS CUI [1,4])
C1527304 (UMLS CUI [2,1])
C0068006 (UMLS CUI [2,2])
C1706082 (UMLS CUI [2,3])
C2348205 (UMLS CUI [2,4])
C1527304 (UMLS CUI [3,1])
C0044549 (UMLS CUI [3,2])
C1706082 (UMLS CUI [3,3])
C2348205 (UMLS CUI [3,4])
Hypersensitivity Thalidomide
Item
known hypersensitivity to thalidomide
boolean
C0020517 (UMLS CUI [1,1])
C0039736 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial